Aquestive Therapeutics (AQST) Gains from Investment Securities (2017 - 2026)
Aquestive Therapeutics (AQST) recorded quarterly Gains from Investment Securities of $329000.0 in Q1 2026, up 141.54% quarter-over-quarter from -$792000.0 in Q4 2025, and up 815.22% on a YoY basis from $35947.7 in Q1 2025.
Aquestive Therapeutics (AQST) Gains from Investment Securities (2017 - 2026) Analysis & Trends
Aquestive Therapeutics' Gains from Investment Securities history runs 10 years deep, the most recent figure standing at $329000.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 815.22% year-over-year to $329000.0; the TTM figure through Mar 2026 stood at $375000.0 (up 131.48% YoY), while the FY2024 annual figure was $1.1 million, changed N/A from the prior year.
- Gains from Investment Securities was $329000.0 for Q1 2026 at Aquestive Therapeutics, up from -$792000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $893000.0 in Q1 2024 to a low of -$792000.0 in Q4 2025.
- Historically, Gains from Investment Securities has averaged $92625.0 across 5 years, with a median of $27000.0 in 2023.
- The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities surged 11062.5% in 2024, then sank 79300.0% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at $49000.0 in 2022, then slumped by 122.45% to -$11000.0 in 2023, then surged by 109.09% to $1000.0 in 2024, then tumbled by 79300.0% to -$792000.0 in 2025, then surged by 141.54% to $329000.0 in 2026.
- The last three Gains from Investment Securities figures came in at $329000.0 (Q1 2026), -$792000.0 (Q4 2025), and $792000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn |
| 10 | Aquestive Therapeutics | 487.99 Mn | 377.25 Mn | 10.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 329,000.00 |
| Mar 31, 2026 | 329,000.00 |
| Dec 31, 2025 | -792,000.00 |
| Dec 31, 2025 | -792,000.00 |
| Sep 30, 2025 | 792,000.00 |
| Sep 30, 2025 | 792,000.00 |
| Jun 30, 2025 | 46,000.00 |
| Jun 30, 2025 | 46,000.00 |
| Mar 31, 2025 | -46,000.00 |
| Mar 31, 2025 | -46,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | 202,000.00 |
| Sep 30, 2024 | 202,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Mar 31, 2024 | 893,000.00 |
| Mar 31, 2024 | 893,000.00 |
| Sep 30, 2023 | -11,000.00 |
| Sep 30, 2023 | -11,000.00 |